Compare AZTA & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | SPTX |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2026 |
| Metric | AZTA | SPTX |
|---|---|---|
| Price | $24.51 | $21.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $40.60 | N/A |
| AVG Volume (30 Days) | ★ 706.6K | 212.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $593,821,000.00 | N/A |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $5.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $17.59 |
| 52 Week High | $41.73 | $22.98 |
| Indicator | AZTA | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 59.79 |
| Support Level | $21.88 | N/A |
| Resistance Level | $32.99 | $22.98 |
| Average True Range (ATR) | 1.17 | 1.76 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 51.78 | 46.24 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.